Novagali Pharma specialised in developing ocular therapeutics for different segments of the eye (surface, anterior and posterior segments). Their formulations were based on proprietary technology platforms Novasorb® and Eyeject®, which optimized bioavailability of drugs as well as safety and comfort for the patient. Novagali Pharma was acquired by Santen for $139 million in 2011.